Arvinas Androgen Receptor, Inc.
Arvinas is a clinical-stage biotechnology company focused on developing targeted protein degradation therapeutics using their revolutionary PROTAC platform. They aim to transform drug discovery by creating innovative medicines that target and degrade disease-related proteins, including those considered 'undruggable'. With a strong commitment to scientific innovation, Arvinas is advancing a pipeline of investigational drugs in oncology and neuroscience, striving to bring new options to patients with serious diseases.
Industries
Nr. of Employees
large (251-1000)
Arvinas Androgen Receptor, Inc.
5 Science Park, 395 Winchester Ave., New Haven, CT 06511
Patents
Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US-12036209-B2
View DetailsCompounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US-11065231-B2
View Details
Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US-12036209-B2
View DetailsCompounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US-11065231-B2
View DetailsProducts
Clinical-stage investigational targeted protein degraders
Investigational small-molecule degraders designed to selectively induce degradation of disease-associated proteins; programs span oncology and neurodegeneration and are in various stages of clinical development.
Clinical-stage investigational targeted protein degraders
Investigational small-molecule degraders designed to selectively induce degradation of disease-associated proteins; programs span oncology and neurodegeneration and are in various stages of clinical development.
Services
Strategic partnerships for co-development, licensing, and commercialization of investigational targeted protein degraders.
Strategic partnerships for co-development, licensing, and commercialization of investigational targeted protein degraders.
Expertise Areas
- Targeted protein degradation
- Medicinal chemistry and small-molecule design
- Translational development and pipeline progression
- Clinical trial management and execution
Key Technologies
- Targeted protein degradation (PROTACs)
- Induced proximity / E3 ligase recruitment
- Ubiquitin–proteasome system exploitation
- Small-molecule medicinal chemistry